inhibition of Tumor Growth Through Reduction of Peroxiredoxin 3 levels

The primary transforming activity of MYC is thought to arise through transcriptional regulation of numerous target genes. Scientists at Johns Hopkins have demonstrated that PRDX3, which encodes a mitochondrial protein of the peroxiredoxin gene family, is a direct target of MYC and is required for MYC-mediated transformation. These observations are consistent with the finding that PRDX3 protein levels are frequently elevated in breast cancer cells. Importantly, Hopkins researchers found that reducing PRDX3 expression level results in a profound inhibition of tumor formation. Description (Set) Proposed Use (Set) Interruption of PRDX3 protein expression and/or function may be useful in preventing MYC-mediated cancer development. Furthermore, disruption of mitochondrial homeostasis via PRDX3 may be an effective means of treating established tumors. Patent (Set) WO 03/087312

Patents:
US 3,087,312

Inventor(s): Dang, Chi V.

Type of Offer: Licensing



« More Pharmaceutical Patents

---